iPSC CAR NK cells
Cytovia and its scientific partners aim to design the next generation of CAR (Chimeric Antigen Receptor) NK Cell Therapy products by selecting appropriate target antigens and applying synthetic biology/gene editing tools to increase the precision and persistence of NK cells, thereby improving their clinical efficacy and safety.
The chimeric antigen receptor (CAR) is an artificially modified fusion protein that consists of an extracellular antigen recognition domain fused to an intracellular signaling domain. NK cells genetically modified with a CAR have demonstrated initial clinical success in the treatment of hematological cancers.
CAR NK Cell Therapy has the same potent effector machinery as T-cell Therapy but does not cause Graft Vs Host Disease (GVHD) or Cytokine Release Syndrome (CRS) (observed with T-cell and CAR T-cell therapy).
Allogeneic CAR NK are safe off the shelf products and can potentially be administered in an out patient setting.
Cytovia’s focus is on differentiation and expansion of NK cells from Induced Pluripotent Stem Cells (iPSCs) and Gene Editing to optimize CAR design. (Learn More)
2012 Medicine Nobel Prize Professor Yamanaka (Kyoto University) discovered Induced Pluripotent Stem Cells (iPSCs), demonstrating that mature adult cells can be transformed into stem cells
A single clone can produce a master cell bank allowing for thousands of consistent doses per batch, significantly more cost-effective than autologous or even other allogeneic cell therapy
iPSC derived NK and CAR NK cells are easier for gene-editing expanding opportunities for precision and persistency enhancement.